Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

875 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The role of allogeneic stem cell transplantation in Hodgkin's lymphoma.
Sureda A, Domenech E, Schmitz N, Dreger P; Lymphoma Working Party of the European Group for Stem Cell Transplantation. Sureda A, et al. Curr Treat Options Oncol. 2014 Jun;15(2):238-47. doi: 10.1007/s11864-014-0287-3. Curr Treat Options Oncol. 2014. PMID: 24752768 Review.
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J; AETHERA Study Group. Moskowitz CH, et al. Among authors: sureda a. Lancet. 2015 May 9;385(9980):1853-62. doi: 10.1016/S0140-6736(15)60165-9. Epub 2015 Mar 19. Lancet. 2015. PMID: 25796459 Clinical Trial.
Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy.
Martínez C, Díaz-López A, Rodriguez-Calvillo M, García-Sanz R, Terol MJ, Pérez-Ceballos E, Jiménez MJ, Cantalapiedra A, Domingo-Domenech E, Rodriguez MJ, Sampol A, Espeso M, López FJ, Briones J, García JF, Sureda A; Hodgkin Lymphoma Subcommittee of Spanish Group of Lymphoma Bone Marrow Transplantation(GELTAMO). Martínez C, et al. Among authors: sureda a. Br J Haematol. 2016 Sep;174(6):859-67. doi: 10.1111/bjh.14133. Epub 2016 May 17. Br J Haematol. 2016. PMID: 27185197 Free article. Clinical Trial.
Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.
Epperla N, Ahn KW, Ahmed S, Jagasia M, DiGilio A, Devine SM, Jaglowski S, Kennedy V, Rezvani AR, Smith SM, Sureda A, Fenske TS, Kharfan-Dabaja MA, Armand P, Hamadani M. Epperla N, et al. Among authors: sureda a. J Hematol Oncol. 2017 Jun 12;10(1):117. doi: 10.1186/s13045-017-0487-y. J Hematol Oncol. 2017. PMID: 28606176 Free PMC article.
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group. Horwitz S, et al. Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4. Lancet. 2019. PMID: 30522922 Free PMC article. Clinical Trial.
m7FLIPI and targeted sequencing in high-risk follicular lymphoma.
Sorigue M, Oliveira A, Mercadal S, Tapia G, Climent F, Perez-Roca L, Lorences I, Domingo-Domenech E, Cabezon M, Navarro JT, Gonzalez-Barca E, Zamora L, Ribera JM, Sureda A, Armengol MP, Sancho JM. Sorigue M, et al. Among authors: sureda a. Hematol Oncol. 2019 Dec;37(5):564-568. doi: 10.1002/hon.2674. Epub 2019 Oct 25. Hematol Oncol. 2019. PMID: 31475375
Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution.
Salas MQ, Mercadal S, Domingo Domenech E, Oliveira AC, Encuentra M, Climent F, Andrade Campos M, Aguilera C, Fernández de Sevilla A, Sureda A, González-Barca E. Salas MQ, et al. Among authors: sureda a. Leuk Lymphoma. 2020 Mar;61(3):575-581. doi: 10.1080/10428194.2019.1683733. Epub 2019 Nov 5. Leuk Lymphoma. 2020. PMID: 31684781
Clinicopathologic features and prognostic significance of CD30 expression in de novo diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution.
Salas MQ, Climent F, Tapia G, DomingoDomènech E, Mercadal S, Oliveira AC, Aguilera C, Olga G, Moreno Velázquez M, Andrade-Campos M, Encuentra M, Fernández de Sevilla A, Sureda A, Sancho JM, González-Barca E. Salas MQ, et al. Among authors: sureda a. Biomarkers. 2020 Feb;25(1):69-75. doi: 10.1080/1354750X.2019.1691656. Epub 2019 Nov 21. Biomarkers. 2020. PMID: 31752540
875 results